Tom Allen

1 week ago | computing.co.uk | Tom Allen

Intruder accessed historic personal data Oxford City Council (OCC) detected and shut down an “unauthorised presence” in its network, although the attackers still managed to access some data. According to the council’s statement the intruder was able to access “historic data on legacy systems” over the weekend of 7th and 8th June.

1 week ago | aijourn.com | Tom Allen

AI is developing at lightning speed. As fast as it changes and grows, so do the discussions around it. Creative people—writers, designers, photographers, and illustrators—may have one opinion on a Monday and another two weeks later. Add the phenomenon’s unknowns to the mix, and you don’t know what to think. The Scare We ShareOnly two years ago, we started seeing the first AI-generated images created by regular folks, and we laughed at seven-fingered hands and missing ears.

1 week ago | computing.co.uk | Tom Allen

Plus: Chinese chip bans may have backfired Welcome to Computing's weekly roundup of tech news in Asia. This time we look at the results of Australia’s age assurance trials, plus signs of regret over US chip bans to China. Restricting access to online sites based on age is controversial for several reasons, not least of which are questions over the effectiveness of age assurance technologies.

1 week ago | aijourn.com | Tom Allen

Among the market leaders in cloud technology, Amazon Web Services (AWS) stands out for its broad portfolio, reliability, and extensive global footprint. However, cloud migrations have unique challenges—especially when transitioning complex systems from on-premise environments to AWS. DevOps plays a pivotal role in providing organizations with methodologies, tools, and practices that streamline migrations and ensure smooth operations post-transition.

1 week ago | aijourn.com | Tom Allen

Clinical trials are the bedrock of medical advancement, yet patient recruitment remains one of the most persistent and costly bottlenecks in the drug development lifecycle. Delays in enrollment can significantly inflate trial costs, extend timelines, and ultimately delay life-saving treatments from reaching patients.